Biopharma AI
By
Could Merck’s USD 349M Collaboration with Variational AI and Its Enki™ Platform Mark a Turning Point for Generative-AI-Designed Small Molecules?
Key Highlights A Strategic Alliance Targeting Hard-to-Crack Therapeutic SpaceVariational AI announced a major collaboration with Merck to deploy…
Could Excelsior Sciences’ $95M AI Surge Redefine How Fast Small-Molecule Drugs Reach the Market?
Key Highlights • $95M funding round positions Excelsior to compress multi-month chemistry cycles into weeks, reshaping competitive timelines…
Will Novartis’s $12 Billion Avidity Deal Ignite a New Era of AI-Powered RNA Therapeutics and Transform Rare-Disease Innovation?
Key Insights:• Novartis AG acquires Avidity Biosciences for $12 billion (USD 72 per share) — the company’s largest…
Can Eli Lilly and NVIDIA’s AI Supercomputer Redefine Drug Discovery Timelines and Ignite a $40 Billion AI-Biopharma Revolution?
Key Insights:• Lilly builds one of pharma’s first NVIDIA-powered DGX SuperPODs, training AI on millions of experiments to…
Can Johnson & Johnson’s $350 Million AI Investment in 2025 Transform Drug Discovery, R&D, and Commercial Success in 2026?
Global – December 31, 2025 — Johnson & Johnson significantly expanded its use of artificial intelligence (AI) across…
AbbVie Invested $400 Million in AI in 2025: How This Will Transform Discovery, R&D, and Commercialization in 2026
Global – December 31, 2025 — AbbVie Inc. significantly expanded the integration of artificial intelligence (AI) and data-driven…
